Latitude Tissue-Free MRD
Use
Latitude™ is a tissue-free, blood-based residual disease test (MRD) specifically designed for colorectal cancer (CRC) patients. It provides crucial information about a patient’s disease status post-operatively and during post-definitive treatment surveillance. The test offers high sensitivity and specificity for detecting residual disease in CRC patients. In clinical studies, Latitude™ helped identify which patients could benefit from adjuvant chemotherapy (ACT) and provided early indication of relapse, illustrating a median lead time of 4.6 months before radiographic relapse.
Special Instructions
Latitude™ does not require tumor tissue for analysis, making it easier and more convenient for patients. The test can integrate into existing clinical workflows to support treatment decisions for colorectal cancer patients who have undergone surgery.
Limitations
The sensitivity of the Latitude™ test varies according to the time of testing. Post-operative sensitivity is reported at 58%, while longitudinal sensitivity during surveillance is higher at 84% and 87% for colon cancer specifically. The specificity of the test is reported to be 97%, which may have implications for interpreting results, especially in relation to treatment decisions.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided